Needham Downgrades Geron (GERN) to Hold
GERN Hot Sheet
Rating Summary:1 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Needham & Co. downgrades Geron (Nasdaq: GERN) from Buy to Hold.
Visit our Analyst Ratings page to see all the upgrades/downgrades on shares of Geron.
Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.
Visit our Analyst Ratings page to see all the upgrades/downgrades on shares of Geron.
Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.
You May Also Be Interested In
- UPDATE: UBS Downgrades Avon Products (AVP) to Sell; Still Cautious Even After Sell Off
- Guggenheim Initiates Coverage on Several Oil & Gas Drilling & Exploration Stocks; Upgrades DO & ESV, Lowers RDC
- Sterne Agee Downgrades Assurant (AIZ) to Underperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
